Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T21:50:06.181Z Has data issue: false hasContentIssue false
  • English
  • Français

Malaria Protection of the International Traveler

Published online by Cambridge University Press:  21 June 2016

M. Sigfrido Rangel-Frausto  and
Michael B. Edmond
M. Sigfrido Rangel-Frausto
Affiliation:
Department of Internal Medicine, Division of General Medicine, Clinical Epidemiology, and Health Services Research, University of Iowa College of Medicine, Iowa City, Iowa
Michael B. Edmond*
Affiliation:
Department of Internal Medicine, Division of General Medicine, Clinical Epidemiology, and Health Services Research, University of Iowa College of Medicine, Iowa City, Iowa
*
C31H GH, University of Iowa Hospitals and Clinics, Iowa City, IA 52242
Get access Rights & Permissions [Opens in a new window]

Extract

Although isolated cases of malaria still may be acquired in the United States,’ imported cases in international travelers are primarily responsible for approximately 1,000 cases reported annually to the Centers for Disease Control and Prevention (CDC). In the decade ending in 1988, more than 50 malaria-associated deaths were reported, most of them theoretically preventable. Moreover, it is estimated that only 30% to 60% of malaria cases are actually reported to the CDC.

In recent years, an increase in infections due to Plasmodium falciparum, which accounts for the most severe form of malaria, has been noted. This increase is multifactorial in origin and is associated with an increase in travel to malarious areas, difficulties with chemoprophylaxis (including compliance and adverse effects), and increasing resistance to multiple antimalarial agents. Thus, careful counseling of the traveler and appropriate chemoprophylaxis remain vitally important.

Type
Emporiatrics
Information
Infection Control & Hospital Epidemiology , Volume 14 , Issue 3 , March 1993 , pp. 155 - 160
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Centers for Disease Control. Mosquito-transmitted malaria—California and Florida, 1990. MMWR. 1991;40:106–108.Google Scholar
2. Centers for Disease Control. Summary of notifiable diseases, United States, 1990. MMWR. 1991;39:55–61.Google Scholar
3. Lobel, HO. Malaria and use of preventive measures among United States travelers. In: Steffen, R, Lobel, HO, Haworth, J, Bradley, DI, eds. Travel Medicine. New York NY: Springer-Verlag; 1988:81–89.Google Scholar
4. Malaria Surveillance, Annual Summary, 1988. Atlanta, Ga: Centers for Disease Control; 1988.Google Scholar
5. Breckenridge, A. Risks and benefits of orqohylactic antimalarial drugs. BMJ. 1989;299:1057–1058.CrossRefGoogle ScholarPubMed
6. Oaks, SC, Mitchell, VS, Pearson, GW, Carpenter, CCJ, eds. Malaria: Obstacles and Opportunities. Washington, DC: National Academy Press; 1991.Google Scholar
7. Health Information for International Travel 1992. Atlanta, Ga: Centers for Disease Control; 1992. US Dept. of Health and Human Services Publication CDC 92-8280.Google Scholar
8. Miller, LH, Warrell, DA. Malaria. In: Warren, KS, Mahmoud, AAE Tropical and Geographical Medicine. 2nd ed. New York, NY: McGraw-Hill; 1990:245–264.Google Scholar
9. Bruce-Chwatt, LJ. Essential Malariology. 2nd ed. London, England William Heinemann Medical Books Ltd; 1985.Google Scholar
10. International Travel and Health: Vaccination Requirements and Health Advice. Geneva, Switzerland: World Health Organization; 1992.Google Scholar
11. Hall, R. Malaria prevention. Med JAustr. 1992;156:103–108.Google ScholarPubMed
12. Cook, GC. Prevention and treatment of malaria. Lancet. 1988;i:32–37.CrossRefGoogle Scholar
13. Snow, WE Trials with an electronic mosquito-repelling device in Western Africa. Trans R Soc Trop MedHyg. 1977;71:449–450.CrossRefGoogle Scholar
14. Steffen, R, Heusser, R, Machler, R, et al. Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reaction, and efficacy. Bull World Health Organ. 1990;68:313–322.Google Scholar
15. Kollaritsch, H, Wiedermann, G. Compliance of Austrian tourists with prophylactic measures. Eur J Epidemiol. 1992;8:243–251.CrossRefGoogle ScholarPubMed
16. Keystone, JS. Prevention of malaria. Drugs. 1990;39:337–354.CrossRefGoogle ScholarPubMed
17. Harries, AD, Chugh, KS. Chloroquine-induced pruritus in Nigerian medical and nursing students. Ann Trop Med Barasitol. 1986;80:479–480.CrossRefGoogle ScholarPubMed
18. Desjardins, RE, Doberstyn, EB, Wernsdorfer, WH. The treatment and prophylaxis of malaria. In: Wernsdorfer, WH, McGregor, I, eds. Malaria: Principles and Practice of Malariology. Vol. 1, 1st ed. New York, NY: Churchill Livingstone; 1988:827–864.Google Scholar
19. Riou, B, Barriot, P, Rimahilho, A, Baud, E, Treatment of severe chloroquine poisoning. N Engl J Med. 1989;321:1415.Google Scholar
20. Fitch, CD, Chevil, R, Banyal, HS, Philip, G, Pfaller, MA, Krogstad, DJ. Lysis of P falciparum by ferroprotoporphyrin IX and a chloroquine-ferroprotoporphyrin IX complex. Antimicrob Agents Chemother. 1982;21:819–822.CrossRefGoogle Scholar
21. Herwaldt, BL, Krogstad, DJ, Schlessinger, PH. Antimalarial agents: specific chemoprophylaxis regimens. Antimicrob Agents Chemother. 1988;32:953–956.CrossRefGoogle ScholarPubMed
22. Chevli, R, Fitch, CD. The antimalarial drug mefloquine binds to membrane phospholipids. Antimicrob Agents Chemother. 1982;21:581–586.CrossRefGoogle ScholarPubMed
23. Bem, JL, Kerr, L, Stuerchler, D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg. 1992:95:167–179.Google ScholarPubMed
24. Coosemans, MH, Barutwanayo, M, Onori, E, Otoul, C, Gryseels, B, Wery, M. Double-blind study to assess the efficacy of chlorproguanil given alone or in combination with chloroquine for malaria chemoprophylaxis in an area with Plasmodium falciparum resistance to chloroquine, pyrimethamine and cycloguanil. Trans R Soc Trop Med Hyg. 1987;81:151–156.CrossRefGoogle ScholarPubMed
25. Henderson, A, Simon, JW, Melia, W. Failure of malaria chemoprophylaxis with a proguanil-chloroquine combination in Papua New Guinea. Trans R Soc Trop Med Hyg. 1986;80:838–840.CrossRefGoogle ScholarPubMed
26. Gozal, D. Hengy, C. Gilles, F. Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance. Antimicrob Agents Chemother. 1991;35:373–376.10.1128/AAC.35.2.373CrossRefGoogle Scholar
27. Gozal, D, Giles, F, Hengy, C. Long-term chloroquine-proguanil malaria prophylaxis in a nonimmune pediatrie population. J Pediatrics. 1991;118:142–145.CrossRefGoogle Scholar
28. Shanks, GD, Edstein, MD, Suriyamongkol, V, Timsaad, S, Webster, HK. Malaria chemoprophylaxis using proguanil/dapsone combinations on the Thai-Cambodian border. Am J Trop Med Hyg. 1992;46:643–648.CrossRefGoogle ScholarPubMed
29. Karwacki, JJ, Shanks, GD, Suriyamongkol, V, Watanasook, C. Proguanil/sulfamethoxazole malaria chemoprophylaxis on the Thai-Cambodian border. Southeast Asian J Trop Med Public Health. 1991;22:77–80.Google Scholar
30. Pang, LW, Limsomwong, N, Singharaj, P, Canfield, CJ. Malaria prophylaxis with proguanil and sulfisoxazole in children living in a malaria endemic area. Bull World Health Organ. 1989;67:51–58.Google Scholar
31. Pang, LW, Boudreau, EF, Limsomwong, N, Singharaj, P Doxycy-cline for falciparum malaria. Luncet. 1987;ii: 1161–1164.10.1016/S0140-6736(87)92141-6CrossRefGoogle Scholar
32. Geary, TG, Jensen, JB. Effects of antibiotics on Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1983;32:221–225.CrossRefGoogle ScholarPubMed
33. Menter, JM. Recent developments in UVA photoprotection. Int J Dermatol. 1990;29:389–394.CrossRefGoogle ScholarPubMed
34. Luftman, DB, Lowe, NJ, Moy, RL. Sunscreens: update and review. J Dermatol Surg Oncol. 1991;17:744–746.CrossRefGoogle ScholarPubMed
35. Sakmar, TP, The traveler's medical kit. Infect Dis Clin North Am. 1992;6:355–370.CrossRefGoogle ScholarPubMed
36. Miller, KD, Lobel, HO, Satriale, RF, Kuritsky, JN, Stern, R, Campbell, CC. Severe cutaneous reactions among American travelersusingpyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986;35:451–458.10.4269/ajtmh.1986.35.451CrossRefGoogle ScholarPubMed
37. Centers for Disease Control. Malaria in travelers returning from Kenya: failure of self-treatment with pyrimethamine/ sulfadoxine. MMWR. 1989;38:363–364.Google Scholar
38. Subramanian, D, Moise, KJ Jr, White, AC Jr. Imported malaria in pregnancy: report of four cases and review of management. Clin Infect Dis. 1992;15:408–413.CrossRefGoogle ScholarPubMed
39. Certa, II. Malaria vaccine. Experientia. 1991;47:157–163.CrossRefGoogle ScholarPubMed
40. Amador, R, Moreno, A, Murillo, LA, et al. Safety and immunogenicity of the synthetic malaria vaccine SPF66 in a large field trial. J Infect Dis. 1992;166:139–144.CrossRefGoogle Scholar